In a groundbreaking development that could revolutionize colorectal cancer diagnostics, researchers have unveiled compelling evidence linking the epigenetic silencing of the microRNA gene miR-139-5p to the pathogenesis of colorectal cancer (CRC). This discovery not only deepens our molecular understanding of CRC but also suggests a highly accurate, non-invasive biomarker for early detection of the disease through plasma samples.
Colorectal cancer is one of the most common malignancies worldwide and remains a leading cause of cancer-related mortality. Its multifactorial etiology includes a complex interplay of genetic mutations alongside epigenetic alterations—heritable yet reversible changes in gene expression without modifications to the underlying DNA sequence. Among these mechanisms, DNA methylation at CpG islands within gene promoter regions plays a pivotal role by silencing tumor suppressor genes or regulatory non-coding RNAs, tipping the cellular environment toward malignancy.
The study meticulously evaluated the methylation status of the miR-139-5p promoter region in tumor tissues and corresponding plasma samples from patients diagnosed with CRC. miR-139-5p, known for its tumor-suppressive functions, was previously hypothesized to be epigenetically silenced in various cancers, but concrete data in colorectal cancer were lacking. Employing the highly sensitive MethyLight technique, which quantifies DNA methylation levels with precision, the researchers analyzed 80 paired samples of tumorous and adjacent healthy tissues, along with matched plasma specimens.
To assess the functional consequences of methylation, expression levels of miR-139-5p were measured via quantitative PCR (qPCR), providing a robust correlation between gene silencing and epigenetic modification. Furthermore, the study investigated the concentration of RAP-1b protein, a direct target gene suppressed by miR-139-5p, through ELISA assays, thereby linking molecular changes to phenotypic outcomes relevant in oncogenesis.
Results displayed a striking difference in methylation between cancerous and non-cancerous plasma samples, with median percentage of methylated reference (PMR) values approximately 12.4 in CRC patients versus as low as 0.66 in controls. This disparity underscores the robustness of miR-139-5p promoter methylation as a biomarker signature. Sensitivity and specificity for CRC detection in plasma samples were calculated at 75% and 92.5% respectively, yielding an outstanding area under the receiver operating characteristic curve (AUC) of 0.958, which highlights the excellent diagnostic potential of this epigenetic marker.
Additionally, the inverse relationship between miR-139-5p expression and RAP-1b protein concentration bolsters the molecular narrative where hypermethylation leads to silencing of the microRNA, thus relieving repression of oncogenic RAP-1b, contributing to tumor proliferation and progression. The statistically significant decrease in miR-139-5p expression in both plasma and tumoral tissue (<0.001, p-value) confirms the functional impact of methylation-mediated gene silencing within the CRC pathophysiological framework.
The researchers emphasize that plasma-based detection of miR-139-5p hypermethylation offers a minimally invasive and potentially cost-effective strategy for early CRC diagnosis. Current screening methods such as colonoscopy, although highly effective, face limitations including invasiveness, cost, and patient compliance. Liquid biopsy approaches, analyzing circulating tumor-derived DNA in blood, represent the frontier in precision oncology diagnostics. This study’s findings mark a critical stride toward integrating epigenetic biomarkers into routine clinical workflows.
While promising, the authors caution that additional large-scale prospective studies are essential to validate these findings across diverse populations and to evaluate longitudinal changes during treatment and disease remission. Determining the stability and dynamics of miR-139-5p methylation in plasma over time will be crucial to establishing its utility not only as a diagnostic tool but possibly as a prognostic or surveillance marker.
Moreover, this work aligns with increasing recognition of microRNAs’ central roles in cancer biology. These small non-coding RNAs regulate gene expression post-transcriptionally and are often dysregulated in malignancies. Epigenetic repression of microRNAs, such as miR-139-5p, illustrates a mechanism by which cancer cells circumvent tumor suppressive pathways, a concept that may extend to other miRNAs and cancer types.
Technically, the employment of MethyLight technology represents a gold standard for methylation quantitation, capable of detecting low-abundance methylated molecules even in heterogeneous samples like plasma. Coupled with qPCR and ELISA, the study offers a comprehensive, multimodal approach to dissecting the miR-139-5p/RAP-1b axis at DNA, RNA, and protein levels.
The integration of epigenetic biomarkers with conventional diagnostic methods could enhance sensitivity and specificity, reducing false positives and negatives that plague current cancer screening tests. Furthermore, since epigenetic changes are reversible, understanding the methylation landscape opens avenues for therapeutic interventions using demethylating agents, tailoring treatment to molecular profiles.
This study’s implications transcend colorectal cancer as the paradigm of epigenetic microRNA silencing could be applicable to multiple tumor entities where miR-139-5p or similar microRNAs function. Personalized medicine stands to benefit tremendously by incorporating such biomarkers into decision-making algorithms, optimizing patient outcomes.
In conclusion, the hypermethylation of miR-139-5p promoter DNA emerges as a highly promising plasma-based biomarker for colorectal cancer detection with impressive diagnostic accuracy. The work propels us closer to realizing non-invasive, precise blood tests capable of early cancer diagnosis, ultimately reducing mortality through timely intervention. The scientific community eagerly awaits further validation studies to transform this molecular insight into clinical reality, heralding a new era in oncologic diagnostics driven by epigenetic research.
Subject of Research: Epigenetic silencing of the microRNA gene miR-139-5p and its role in colorectal cancer pathogenesis and plasma-based diagnostic biomarker potential.
Article Title: Evaluation of epigenetic silencing of the miR-139-5p gene in the pathogenesis of colorectal cancer and its diagnostic biomarker capability in plasma samples
Article References:
Asefi, M., Rezvani, N., Saidijam, M. et al. Evaluation of epigenetic silencing of the miR-139-5p gene in the pathogenesis of colorectal cancer and its diagnostic biomarker capability in plasma samples. BMC Cancer 25, 877 (2025). https://doi.org/10.1186/s12885-025-14290-x
Image Credits: Scienmag.com
DOI: https://doi.org/10.1186/s12885-025-14290-x
Tags: cancer-related mortality factorscolorectal cancer diagnosticsDNA methylation in cancerearly detection of colorectal cancerepigenetic alterations in malignanciesepigenetic silencing of microRNAmethylation status analysismicroRNA gene expressionmiR-139-5p colorectal cancer biomarkernon-invasive cancer detectionplasma samples for cancer screeningtumor suppressor genes in CRC